Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression
Purpose: This manuscript explores the potential of dual glucagon-like peptide 1 (GLP-1) agonists combined with degludec basal insulin as a treatment approach for early type 1 diabetes. The study aims to evaluate the efficacy and mechanistic impact of semaglutide, a GLP-1 agonist, on newly diagnosed...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tabriz University of Medical Sciences
2024-07-01
|
| Series: | Advanced Pharmaceutical Bulletin |
| Subjects: | |
| Online Access: | https://apb.tbzmed.ac.ir/PDF/apb-14-262.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850078181574311936 |
|---|---|
| author | Amr Ahmed Maher Monir. Akl |
| author_facet | Amr Ahmed Maher Monir. Akl |
| author_sort | Amr Ahmed |
| collection | DOAJ |
| description | Purpose: This manuscript explores the potential of dual glucagon-like peptide 1 (GLP-1) agonists combined with degludec basal insulin as a treatment approach for early type 1 diabetes. The study aims to evaluate the efficacy and mechanistic impact of semaglutide, a GLP-1 agonist, on newly diagnosed type 1 diabetes patients. Methods: A retrospective analysis was conducted to assess the effects of semaglutide on individuals with early type 1 diabetes. The analysis focused on the elimination of prandial and basal insulin, changes in C-peptide levels, and overall glycemic control. The study also examined the potential for GLP-1 agonists to protect residual beta cells, stimulate cell proliferation, and reprogram liver cells into insulin-producing cells. Additionally, the modification of GLP-1 agonists with albumin ligands to extend their half-life and enhance their anti-diabetic effects was investigated. Results: The findings demonstrate the elimination of both prandial and basal insulin requirements, an increase in C-peptide levels, and improved glycemic control among the patients. Despite the positive outcomes, the study’s retrospective nature and absence of a control group highlight the necessity for larger, prospective trials. Conclusion: GLP-1 agonists show considerable potential in the management of type 1 diabetes by protecting residual beta cells, promoting cell proliferation, and reprogramming hepatic cells. The integration of modified GLP-1 agonists with albumin ligands could further enhance these effects. The manuscript underscores the need for continued research to fully explore this therapeutic approach. The proposed treatment strategy, which combines the autoimmune hypothesis, the proliferative effects of GLP-1, and albumin ligand modifications, aims to restore beta cell mass and function, thereby improving the quality of life for individuals with type 1 diabetes. Clinical trials are planned for 2024 under the registration ‹Amr Ahmed, Maher M. Akl, Semaglutide GLP1 Agonists with Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basalbolus› (ClinicalTrials.gov Identifier NCT06057077). |
| format | Article |
| id | doaj-art-954d8a48af604386a982df91cc521060 |
| institution | DOAJ |
| issn | 2228-5881 2251-7308 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Tabriz University of Medical Sciences |
| record_format | Article |
| series | Advanced Pharmaceutical Bulletin |
| spelling | doaj-art-954d8a48af604386a982df91cc5210602025-08-20T02:45:37ZengTabriz University of Medical SciencesAdvanced Pharmaceutical Bulletin2228-58812251-73082024-07-0114226226510.34172/apb.2024.040apb-42384Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells ExpressionAmr Ahmed0Maher Monir. Akl1The public health department, MSc degree in gynecology and obstetrics, Riyadh First Health Cluster, Ministry of Health, Saudia Arabia.Department of Chemistry, Faculty of Science, Mansoura University, 35516, Mansoura, Egypt.Purpose: This manuscript explores the potential of dual glucagon-like peptide 1 (GLP-1) agonists combined with degludec basal insulin as a treatment approach for early type 1 diabetes. The study aims to evaluate the efficacy and mechanistic impact of semaglutide, a GLP-1 agonist, on newly diagnosed type 1 diabetes patients. Methods: A retrospective analysis was conducted to assess the effects of semaglutide on individuals with early type 1 diabetes. The analysis focused on the elimination of prandial and basal insulin, changes in C-peptide levels, and overall glycemic control. The study also examined the potential for GLP-1 agonists to protect residual beta cells, stimulate cell proliferation, and reprogram liver cells into insulin-producing cells. Additionally, the modification of GLP-1 agonists with albumin ligands to extend their half-life and enhance their anti-diabetic effects was investigated. Results: The findings demonstrate the elimination of both prandial and basal insulin requirements, an increase in C-peptide levels, and improved glycemic control among the patients. Despite the positive outcomes, the study’s retrospective nature and absence of a control group highlight the necessity for larger, prospective trials. Conclusion: GLP-1 agonists show considerable potential in the management of type 1 diabetes by protecting residual beta cells, promoting cell proliferation, and reprogramming hepatic cells. The integration of modified GLP-1 agonists with albumin ligands could further enhance these effects. The manuscript underscores the need for continued research to fully explore this therapeutic approach. The proposed treatment strategy, which combines the autoimmune hypothesis, the proliferative effects of GLP-1, and albumin ligand modifications, aims to restore beta cell mass and function, thereby improving the quality of life for individuals with type 1 diabetes. Clinical trials are planned for 2024 under the registration ‹Amr Ahmed, Maher M. Akl, Semaglutide GLP1 Agonists with Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basalbolus› (ClinicalTrials.gov Identifier NCT06057077).https://apb.tbzmed.ac.ir/PDF/apb-14-262.pdfearly type 1 diabetestype 2 diabetesdual glp-1 agonistdegludec basal insulinglp-1 agonistscell proliferationinsulin-producing cellsanti-diabetic effectsadult human hepatic tissuemodified glp-1 derivat |
| spellingShingle | Amr Ahmed Maher Monir. Akl Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression Advanced Pharmaceutical Bulletin early type 1 diabetes type 2 diabetes dual glp-1 agonist degludec basal insulin glp-1 agonists cell proliferation insulin-producing cells anti-diabetic effects adult human hepatic tissue modified glp-1 derivat |
| title | Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression |
| title_full | Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression |
| title_fullStr | Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression |
| title_full_unstemmed | Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression |
| title_short | Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression |
| title_sort | exploring a synergistic approach dual glp 1 agonist combined with degludec basal insulin for early type 1 diabetes treatment and its impact on albumin insulin producing cells expression |
| topic | early type 1 diabetes type 2 diabetes dual glp-1 agonist degludec basal insulin glp-1 agonists cell proliferation insulin-producing cells anti-diabetic effects adult human hepatic tissue modified glp-1 derivat |
| url | https://apb.tbzmed.ac.ir/PDF/apb-14-262.pdf |
| work_keys_str_mv | AT amrahmed exploringasynergisticapproachdualglp1agonistcombinedwithdegludecbasalinsulinforearlytype1diabetestreatmentanditsimpactonalbumininsulinproducingcellsexpression AT mahermonirakl exploringasynergisticapproachdualglp1agonistcombinedwithdegludecbasalinsulinforearlytype1diabetestreatmentanditsimpactonalbumininsulinproducingcellsexpression |